Daniel K. Spiegelman - 29 May 2025 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Reporting relationship: Director
Issuer ticker: KYTX
Reported as of: 29 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2025, 18:35:43 UTC
Prior SEC filing: 30 Jan 2025
Next SEC filing: 12 Jun 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Ryan Jones, as Attorney-in-Fact

Key filing fact

Daniel K. Spiegelman filed Form 4 for Kyverna Therapeutics, Inc. (KYTX) on 02 Jun 2025.

Key facts

This page summarizes Daniel K. Spiegelman's Form 4 filing for Kyverna Therapeutics, Inc. (KYTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2025, 18:35.

Change

Previous filing in this sequence was filed on 30 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001238403 Primary reporting owner

SPIEGELMAN DANIEL K

Relationship: Director
Address: C/O KYVERNA THERAPEUTICS, INC., 5980 HORTON ST., STE 550, EMERYVILLE
Signature: By: /s/ Ryan Jones, as Attorney-in-Fact
Signature date: 02 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KYTX transaction

Common Stock

Award

Transaction value: $0
Shares: +16,634
Change %
Price: $0.000000
Shares after: 16,634
Date: 29 May 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KYTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +65,351
Change %
Price: $0.000000
Shares after: 65,351
Date: 29 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,351
Exercise price: $2.63
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Footnote F2

All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.